Abstract
Preclinical HIV prevention models use either a single high-dose viral challenge in depot medroxyprogesterone acetate-treated macaques or repeated viral challenges in cycling macaques. We tested the efficacy of an intravaginal tenofovir disoproxil fumarate (TDF) ring in a model combining repeated 30-mg injections of depot medroxyprogesterone acetate every 6 weeks with vaginal viral challenges weekly for 12 weeks. Twelve macaques were randomized to TDF or placebo rings. All placebo macaques became infected after a median of 2 exposures, whereas only 1 TDF macaque became infected at the eighth exposure (P = 0.0012). The TDF ring provides durable protection in a stringent challenge model.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adenine / administration & dosage
-
Adenine / analogs & derivatives*
-
Adenine / therapeutic use
-
Animals
-
Anti-HIV Agents / administration & dosage
-
Anti-HIV Agents / therapeutic use*
-
Delayed-Action Preparations
-
Female
-
HIV Infections / prevention & control*
-
HIV Infections / transmission
-
Macaca nemestrina
-
Medroxyprogesterone Acetate / administration & dosage*
-
Phosphorous Acids / administration & dosage
-
Phosphorous Acids / therapeutic use*
-
Placebos
-
Simian Acquired Immunodeficiency Syndrome / prevention & control*
-
Simian Acquired Immunodeficiency Syndrome / transmission
-
Vagina*
Substances
-
9-(2-((bis(pivaloyloxymethoxy)phosphinoyl)methoxy)propyl)adenine
-
Anti-HIV Agents
-
Delayed-Action Preparations
-
Phosphorous Acids
-
Placebos
-
Medroxyprogesterone Acetate
-
Adenine